SBIR Phase I: IBEX - Restoring Functional Mobility in the Elderly through In Bed Exercise

SBIR 第一阶段：IBEX - 通过床上锻炼恢复老年人的功能活动能力

• 批准号: 9860355
• 负责人: Robert Dean, Jr.
• 金额: $ 10万
• 依托单位: SYNERGY INNOVATIONS INC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-01-01 至 1999-06-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=9860355&HistoricalAwards=false
• 关键词: SBIR; Phase; IBEX; Restoring; Functional

9860355 This Small Business Innovation Research Phase I project will innovate an In-Bed Exerciser (IBEX). The objective is to restore and/or prevent the loss of functional mobility in bedridden-elderly patients. Functional mobility loss in the elderly often results from rapid muscular atrophy of the thigh and leg muscles during prolonged bed-rest. Decreased functional mobility has a drastic effect on quality of life and has been found to significantly predict mortality. Bedridden-elderly patients depend on physical therapists to provide appropriate exercise at bedside in sessions that are often too infrequent to maintain or rehabilitate deconditioned thigh and leg muscles. Furthermore, physical therapists are unable to sustain sufficient force and intensity to exercise the thigh and leg muscles adequately. Phase I research consists of the design, construction and pilot testing with bedridden patients of a second-generation prototype. The research objectives are to demonstrate the feasibility and safety of IBEX for Phase II clinical trials. The estimated total market of 300,000 Americans is currently served at a cost of $1.4 billion. IBEX will reduce these health care costs by both maintaining and restoring the functional mobility of bedridden patients. IBEX will be used in hospitals, nursing homes and home care settings.

9860355 这个小企业创新研究第一阶段项目将创新床上练习器（IBEX）。目的是恢复和/或预防卧床老年患者的功能活动能力丧失。老年人的功能性活动能力丧失通常是由于长期卧床休息期间大腿和腿部肌肉的快速肌肉萎缩。功能活动性降低对生活质量有显著影响，并被发现可显著预测死亡率。 卧床-老年患者依赖物理治疗师在床边提供适当的锻炼，这些锻炼往往太少，无法维持或恢复失调的大腿和腿部肌肉。此外，物理治疗师无法维持足够的力量和强度来充分锻炼大腿和腿部肌肉。 第一阶段研究包括第二代原型的设计、建造和对卧床不起的患者进行试点测试。研究目的是证明IBEX用于II期临床试验的可行性和安全性。 目前，估计有30万美国人的总市场的服务费用为14亿美元。IBEX将通过维持和恢复卧床不起患者的功能性活动来降低这些医疗保健费用。IBEX将用于医院、疗养院和家庭护理环境。